Interní Med. 2017; 19(5): 258-261 | DOI: 10.36290/int.2017.042

The SURVET study: a new insight into prevention of recurrent venous thromboembolism

MUDr. Jiří Matuška
Angiologická ambulance, MATMED, s. r. o., Hodonín

Venous thromboembolic disease is among the most serious diseases of the circulatory system with an ever-increasing incidence.Treatment has been focused for a long time on the thromboembolic event itself, with the duration of anticoagulant administrationbeing relatively accurately limited. A significant risk of recurrent thromboembolism in a longer time interval has long beenneglected, as has been the pharmacological prevention of this recurrence. The SURVET clinical trial with glycosaminoglycans resultedin a different perspective on this new topic in an era of otherwise predominant use of (novel) direct anticoagulants (NOACs).

Keywords: deep vein thrombosis, pulmonary embolism, recurrent deep vein thormbosis and pulmonary embolism secondary
prevention, sulodexide, NOACs

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matuška J. The SURVET study: a new insight into prevention of recurrent venous thromboembolism. Interní Med. 2017;19(5):258-261. doi: 10.36290/int.2017.042.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Heart Disease and Stroke Statistics - 2016 Update, Circulation 2016; 133: e38. Go to PubMed...
    2. Prandoni P, Noventa F, Ghirarduzzi A, et al. The Risk Of Recurrent Venous Thromboembolism After Discontinuing Anticoagulation In Patients With Acute Proximal Deep Vein Thrombosis Or Pulmonary Embolism. A Prospective Cohort Study In 1,626 Patients,Haematologica February 2007; 92: 199-205. Go to original source... Go to PubMed...
    3. Prandoni P, et al. The long-term clinical course of acute deep venous thrombosis, Ann Intern Med, 1996; 125(1): 1-7. Go to original source... Go to PubMed...
    4. Kahn SR, et al. Effect of postthrombotic syndrome on healthrelated quality of life after deep venous thrombosis. Arch Intern Med. 2002; 162(10): 1144-1148. Go to original source... Go to PubMed...
    5. Ashrani AA, et al. Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: a nested case-control study, Vasc Med. 2010; 15(5): 387-397. Go to original source... Go to PubMed...
    6. Bergqvist D, et al. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden, Ann Intern Med. 1997; 126(6): 454-457. Go to original source... Go to PubMed...
    7. MacDougall DA, et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome, Am J Health Syst Pharm. 2006; 63(20 Suppl 6): S5-15. Go to original source... Go to PubMed...
    8. Couturaud, et al. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism The PADIS- PE Randomzed Clinical Trial, JAMA 2015. Go to original source...
    9. Prandoni, et al. The long-term clinical course of acute deep venous thrombosis, Ann Intern Med 1996; 125: 1-7. Go to original source... Go to PubMed...
    10. Heit JA, et al. Risk Factors for Deep Vein Thrombosis and Pulmonary EmbolismA Population-Based Case-Control Study, Arch Intern Med 2000; 160: 761-768. Go to original source... Go to PubMed...
    11. Baglin T, et al. Risk factors for venous and arterial thrombosis, J Thromb Haemost 2009; 7: 287-290. Go to original source... Go to PubMed...
    12. Savchenko AS, Martinod K, Seidman MA, et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development, J Thromb Haemost. 2014; 12(6): 860-870. doi: 10.1111/jth.12571. Go to original source... Go to PubMed...
    13. Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization, Pflugers Arch. 2007; 454(3): 345-359. Go to original source... Go to PubMed...
    14. Masola V, et al. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects, Int Angiol. 2014; 33(3): 243-254. Go to PubMed...
    15. Lassiera A, et al. A Study on the Safety, Efficacy, and Efficiency of Sulodexide Compared with Acenocoumarol in Secondary Prophylaxis in Patients with Deep Venous Thrombosis, Angiology 2006; 57: 53-64. Go to original source... Go to PubMed...
    16. Errichi BM, et al. Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry, Angiology, 2004; 55: 243-249. Go to original source... Go to PubMed...
    17. Andreozzi GM, Bignamini AA, Davì A, et al. Sulodexide for the Prevention of Recurrent Venous Thromboembolism, Circulation. 2015; 132: 1891-1897. Go to original source... Go to PubMed...
    18. Palareti G, Cosmi B, Legnani C, et al. d-Dimer Testing to Determine the Duration of Anticoagulation Therapy, N Engl J Med 2006; 355: 1780. Go to original source... Go to PubMed...
    19. Fahrni J, Husman M, Gretener SB, et al. Assessing the risk of recurrent venous thromboembolism - a practical approach, Vasc Health Risk Manag. 2015; 11: 451-459. Go to original source... Go to PubMed...
    20. 1. Andreozzi GM, et al. Circulation. 2015; 132: 1891-1897. 2. Simes J, et al. Circulation. 2014; 130: 1060-1071. 3. Schulman S, et al. N Engl J Med. 2013; 368(8): 709-718. 4. The EINSTEIN Investigators. N Engl J Med. 2010; 363: 2499-2510. 5. Agnelli G, et al. N Engl J Med. 2013; 368(8): 699-708.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.